Clinical trial
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular…
NCT00057382 · Tularik, Industry · Terminated
Key facts
| NCT number | NCT00057382 |
|---|---|
| Title | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients |
| Lead sponsor | Tularik, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | T138067 intravenous, doxorubicin intravenous |
| Enrollment | 750 |
| Start date | Mar 1, 2003 |
| First posted | Apr 2, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | Brazil, China, Poland, Puerto Rico, Russia, Singapore, South Africa, Thailand, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: